Maravai LifeSciences Sees Unusually Large Options Volume (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the recipient of unusually large options trading activity on Wednesday. Stock traders bought 1,002 put options on the company. This is an increase of approximately 1,791% compared to the typical volume of 53 put options.

Insiders Place Their Bets

In other Maravai LifeSciences news, CEO Bernd Brust purchased 216,212 shares of the firm’s stock in a transaction dated Thursday, November 13th. The stock was acquired at an average cost of $3.25 per share, with a total value of $702,689.00. Following the acquisition, the chief executive officer owned 466,771 shares of the company’s stock, valued at approximately $1,517,005.75. This represents a 86.29% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Gregory T. Lucier acquired 51,472 shares of the stock in a transaction that occurred on Friday, December 5th. The shares were acquired at an average cost of $3.70 per share, with a total value of $190,446.40. Following the transaction, the director owned 106,595 shares in the company, valued at approximately $394,401.50. The trade was a 93.38% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders acquired 566,771 shares of company stock valued at $1,880,244. 2.11% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Maravai LifeSciences

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Monaco Asset Management SAM increased its stake in Maravai LifeSciences by 315.0% during the 3rd quarter. Monaco Asset Management SAM now owns 3,656,337 shares of the company’s stock valued at $10,494,000 after buying an additional 2,775,372 shares during the period. Tejara Capital Ltd boosted its holdings in shares of Maravai LifeSciences by 257.8% in the second quarter. Tejara Capital Ltd now owns 1,941,449 shares of the company’s stock valued at $4,679,000 after acquiring an additional 1,398,900 shares in the last quarter. First Pacific Advisors LP acquired a new position in shares of Maravai LifeSciences during the second quarter valued at approximately $1,787,000. Immersion Corp increased its stake in shares of Maravai LifeSciences by 153.3% during the second quarter. Immersion Corp now owns 990,000 shares of the company’s stock valued at $2,388,000 after acquiring an additional 599,164 shares during the period. Finally, Harspring Capital Management LLC bought a new stake in Maravai LifeSciences during the second quarter worth approximately $1,205,000. 50.25% of the stock is currently owned by institutional investors.

Maravai LifeSciences Stock Performance

MRVI opened at $3.83 on Thursday. The company has a current ratio of 5.29, a quick ratio of 4.56 and a debt-to-equity ratio of 0.74. The business’s 50 day moving average is $3.60 and its 200-day moving average is $3.06. The stock has a market cap of $979.37 million, a PE ratio of -4.56 and a beta of 0.33. Maravai LifeSciences has a twelve month low of $1.66 and a twelve month high of $6.05.

Maravai LifeSciences (NASDAQ:MRVI) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). The business had revenue of $41.63 million during the quarter, compared to the consensus estimate of $49.02 million. Maravai LifeSciences had a negative return on equity of 22.42% and a negative net margin of 62.88%. On average, analysts predict that Maravai LifeSciences will post -0.24 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Wells Fargo & Company lifted their target price on Maravai LifeSciences from $4.00 to $4.50 and gave the company an “overweight” rating in a research note on Monday, December 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Maravai LifeSciences in a research report on Tuesday, October 14th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $5.25.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.